Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has initiated a plan to repurchase up to 5% of its H Shares by the end of 2024, using internal financial resources to support the company’s value. On 28 August 2024, they made their first repurchase of 1,532,500 H Shares on the open market, spending about HKD18.7488 million. Shareholders are advised to exercise caution, as future repurchases depend on market conditions and regulatory compliance.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
